Actively Recruiting
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
Led by Vanderbilt University Medical Center · Updated on 2025-08-12
75
Participants Needed
1
Research Sites
183 weeks
Total Duration
On this page
Sponsors
V
Vanderbilt University Medical Center
Lead Sponsor
A
ACADIA Pharmaceuticals Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\[18F\]MH.MZ in both populations.
CONDITIONS
Official Title
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of Parkinson disease, diffuse Lewy body disease, multiple systems atrophy, Huntington's Disease, Frontotemporal Dementia, or other related variants
- Age between 50 and 85 years
- Presence of psychosis symptoms (hallucinations or delusions) starting after Parkinson's disease diagnosis, occurring at least weekly for 4 weeks, and severe enough to require treatment
- Availability of a study partner for study visits
- For healthy control arm, age and gender matched to patient arm
You will not qualify if you...
- History of prior stroke or other uncontrolled serious neurological or medical illness
- Contraindication or inability to tolerate MRI scan
- Use of serotonergic medications within the last 6 weeks
- Unable to provide independent consent
- Pregnant or breastfeeding women
- Psychosis caused by metabolic, toxic, or primary psychiatric disease
- Unable to complete neurocognitive testing
- Current or prior use of pimavanserin (for Parkinson disease participants)
- Use of antipsychotic medications within the last 2 weeks
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37212
Actively Recruiting
Research Team
L
Levi Pettit, BA
CONTACT
K
Katie Hay, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here